Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stake Cut by State Street Corp

State Street Corp decreased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 0.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,156,426 shares of the specialty pharmaceutical company’s stock after selling 7,415 shares during the period. State Street Corp owned about 3.91% of Supernus Pharmaceuticals worth $67,237,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Stifel Financial Corp grew its position in shares of Supernus Pharmaceuticals by 1.6% during the 3rd quarter. Stifel Financial Corp now owns 69,134 shares of the specialty pharmaceutical company’s stock valued at $2,156,000 after buying an additional 1,093 shares during the last quarter. Systematic Financial Management LP acquired a new position in Supernus Pharmaceuticals in the third quarter valued at approximately $879,000. HighTower Advisors LLC bought a new position in shares of Supernus Pharmaceuticals during the third quarter valued at approximately $264,000. PDT Partners LLC acquired a new stake in shares of Supernus Pharmaceuticals during the 3rd quarter worth approximately $1,157,000. Finally, Martingale Asset Management L P lifted its holdings in shares of Supernus Pharmaceuticals by 4.6% in the 3rd quarter. Martingale Asset Management L P now owns 37,796 shares of the specialty pharmaceutical company’s stock worth $1,178,000 after purchasing an additional 1,660 shares during the last quarter.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, SVP Frank Mottola sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.98, for a total transaction of $554,700.00. Following the sale, the senior vice president now owns 8,200 shares of the company’s stock, valued at $303,236. The trade was a 64.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Georges Gemayel sold 14,213 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.62, for a total value of $520,480.06. Following the transaction, the director now directly owns 13,315 shares of the company’s stock, valued at approximately $487,595.30. The trade was a 51.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 154,213 shares of company stock valued at $5,660,180. Company insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Trading Down 0.7 %

Shares of NASDAQ SUPN opened at $36.22 on Wednesday. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $39.37. The company has a market cap of $2.00 billion, a PE ratio of 33.85 and a beta of 0.90. The stock has a 50 day simple moving average of $35.47 and a 200-day simple moving average of $32.11.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.25. The company had revenue of $175.70 million during the quarter, compared to analyst estimates of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The firm’s quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.29) EPS. Sell-side analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on SUPN. Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.